An open-label, one-way crossover third phase III study of ALN-AT3 in subjects with severe haemophilia A or B.
Phase of Trial: Phase III
Latest Information Update: 10 Jul 2017
At a glance
- Drugs Fitusiran (Primary)
- Indications Haemophilia A; Haemophilia B
- Focus Registrational; Therapeutic Use
- Acronyms ATLAS-PPX
- 10 Jul 2017 According to a Sanofi Genzyme media release, if positive data will support global regulatory filings for fitusiran.
- 07 Jul 2017 According to an Alnylam Pharmaceuticals media release, top-line data from the ATLAS trials expected in mid-to-late 2019
- 07 Jul 2017 Status changed from planning to recruiting, according to a Sanofi Genzyme media release.